TELA Bio, Inc. (NASDAQ:TELA – Get Free Report) CFO Roberto Cuca purchased 64,444 shares of TELA Bio stock in a transaction dated Thursday, October 24th. The shares were acquired at an average cost of $2.25 per share, with a total value of $144,999.00. Following the transaction, the chief financial officer now directly owns 155,388 shares in the company, valued at approximately $349,623. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
TELA Bio Stock Performance
TELA opened at $2.86 on Friday. The company has a 50 day simple moving average of $2.67 and a two-hundred day simple moving average of $4.15. The company has a debt-to-equity ratio of 14.22, a current ratio of 3.41 and a quick ratio of 2.52. The firm has a market cap of $70.51 million, a P/E ratio of -1.71 and a beta of 0.99. TELA Bio, Inc. has a 1-year low of $2.30 and a 1-year high of $7.84.
TELA Bio (NASDAQ:TELA – Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.06). TELA Bio had a negative return on equity of 252.57% and a negative net margin of 65.04%. The firm had revenue of $16.09 million during the quarter, compared to the consensus estimate of $19.00 million. During the same period in the prior year, the company posted ($0.46) EPS. Equities analysts forecast that TELA Bio, Inc. will post -1.39 earnings per share for the current fiscal year.
Hedge Funds Weigh In On TELA Bio
Analyst Ratings Changes
A number of analysts have commented on the stock. Lake Street Capital reduced their target price on shares of TELA Bio from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Piper Sandler reduced their price objective on TELA Bio from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $12.00 target price on shares of TELA Bio in a report on Friday, October 4th. Finally, JMP Securities cut their price target on TELA Bio from $15.00 to $12.00 and set a “market outperform” rating for the company in a report on Tuesday, August 13th.
Check Out Our Latest Stock Analysis on TELA
About TELA Bio
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Featured Articles
- Five stocks we like better than TELA Bio
- How to Most Effectively Use the MarketBeat Earnings Screener
- Texas Roadhouse Stock Steering for New Highs This Year
- Business Services Stocks Investing
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 3 Warren Buffett Stocks to Buy Now
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.